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Pelvic organ prolapse (POP) is a downward descent of one or more of the pelvic organs,
resulting in a protrusion of the vaginal wall and/or uterus. We performed a genome-wide
association study of POP using data from Iceland and the UK Biobank, a total of 15,010 cases
with hospital-based diagnosis code and 340,734 female controls, and found eight sequence
variants at seven loci associating with POP (P < 5 × 10−8); seven common (minor allele
frequency >5%) and one with minor allele frequency of 4.87%. Some of the variants asso-
ciating with POP also associated with traits of similar pathophysiology. Of these, rs3820282,
which may alter the estrogen-based regulation of WNT4, also associates with leiomyoma of
uterus, gestational duration and endometriosis. Rs3791675 at EFEMP1, a gene involved in
connective tissue homeostasis, also associates with hernias and carpal tunnel syndrome. Our
results highlight the role of connective tissue metabolism and estrogen exposure in the
etiology of POP.
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Pelvic organ prolapse (POP) refers to the condition whereone or more of the pelvic organs herniate to or beyond thevaginal opening and can involve the bladder, uterus, rec-
tum, or post-hysterectomy vaginal cuff1. Symptoms affect quality
of life and include bothersome sense of vaginal bulb, urinary or
bowel symptoms, and sexual dysfunction2–4. The five stages of
POP as defined by Pelvic Organ Prolapse Quantification system
(POPQ)5 range from stage 0; no prolapse, to stage IV which is
complete eversion of the total length of the lower genital tract.
Prevalence estimates for all stages of POP are 30–50% among
postmenopausal women diagnosed on physical examination6–8,
but 7–26% if diagnosis is restricted to pelvic organs herniating
beyond or at the hymenal remnant (stages II–IV)9,10. Symptom-
based prevalence estimates are lower, or 3–6%11,12 with incidence
peaking between ages of 70 and 797. Between 11 and 13% of
women have had surgery for POP or related conditions by age 80
years13–15. POP is the leading indication for hysterectomy in
postmenopausal women and accounts for 1 in 6 hysterectomies in
all age-groups16.
Risk factors for POP vary depending on POP classification. For
POP stages II-IV (a descent at or beyond the hymenal remnant),
risk factors are number of children delivered, vaginal delivery,
advancing age and BMI17, suggesting the role of tissue trauma,
estrogen exposure and intra-abdominal pressure in the patho-
genesis of POP. For all stages of POP, Hispanic ethnicity6, lack of
pelvic floor muscle strength18 and family history19 are also
reported as risk factors, and previous hysterectomy is associated
with severe POP20. For symptomatic POP, poor health status,
constipation, or irritable bowel syndrome are also among repor-
ted risk factors11.
Although the etiology of POP is not fully understood, and is
likely multifactorial, abnormality in the connective tissue sup-
porting the vagina and pelvic organs or in the muscles in the
pelvic floor have been proposed to contribute to the pathophy-
siology of the condition21,22. The pelvic organs’ support is
dependent on interactions between the levator ani muscle and
pelvic connective tissue, i.e. the ligaments holding the organs in
alignment23. A higher prevalence and more recurrent POP is seen
in women with joint hypermobility than in others24,25. Moreover,
higher serum concentration of procollagen III25 is found in
women with joint hypermobility and in those with recurrent
POP. It is, however, unclear whether such changes in collagen
metabolism cause POP or are the result of a trauma26,27.
Genetic factors have been estimated to explain 43% of the
variation in risk of POP in a twin study28. However, previous
candidate gene-, linkage- and genome-wide-association studies
(GWASs) on POP, generally of small sample sizes, have not
yielded sequence variants that associate with POP26,29–31.
To provide insights into the etiology of POP, we performed a
combined GWAS for POP in Iceland and the UK using data on
15,010 cases with hospital-based diagnosis code and 340,734
controls. We discovered eight variants at seven loci that associate
with POP and point to a role of connective tissue metabolism and
estrogen in the etiology of POP.
Results
Association analysis. We performed a meta-analysis of two
GWA-studies on POP, one from Iceland and the other from the
UK (UK Biobank: UKB) with a combined sample of 15,010 cases
and 340,734 controls of European ancestry (Supplementary
Data 1). The Icelandic GWAS included 3409 cases and 131,444
controls and the corresponding numbers from UKB were 11,601
and 209,288. Cases were identified from hospital-based diagnosis
records (International classification of disease (ICD) edition 10
code N81: Female genital prolapse) and controls were all females
(see Methods for a detailed description of the Icelandic and UK
datasets). To account for multiple testing, we used a weighted
Bonferroni procedure based on sequence variant annotation32
(Supplementary Data 2). A total of 245 variants at seven loci
associate with POP at genome-wide significance (Fig. 1 and
Supplementary Fig. 1, Supplementary Data 3). Conditional ana-
lysis at each locus identified a secondary signal at one (2p16.1) of
the seven loci (Supplementary Data 4) resulting in eight distinct
associations with POP (Table 1, Supplementary Fig. 2). All eight
variants were nominally significant in both populations and
accounting for multiple testing (P-value > 0.05/8= 6.25 × 10−3),
there is no significant heterogeneity in the effect estimates from






















Fig. 1 Manhattan plot of association results between sequence variants from Iceland and UK Biobank and pelvic organ prolapse in the meta-analysis.
The significance of association for each variant (P-values on -log10 scale) are plotted against the respective position on each chromosome. Red line
indicates genome-wide significance level (5 × 10−8). Genes closest to the 7 loci of interest are annotated in the Figure. The plot was created using qqman:
an R package for visualizing GWAS results using Q-Q and Manhattan plots102. Variants with imputation information >0.9 are displayed.
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common, with minor allele frequency (MAF) range of 17–48%,
and one is of low frequency (MAF= 4.87%). The number
of variants that correlate with the lead variants (r2 > 0.8) at these
loci ranges from 3 to 78 (Table 1, Supplementary Fig. 2). No
previously suggested POP variants from candidate gene, linkage
or GWAS studies26,29–31 associate with POP (Supplementary
Data 5, 6).
We assessed the robustness of the POP association results
for the eight lead variants in a group of more stringently
diagnosed POP cases that are defined by procedure codes
specific to the treatment of POP in addition to the ICD10 code
N81 (Supplementary Data 7). The statistical power for this
analysis comes mainly from the UKB data because informa-
tion on POP related surgeries was available for 61% of the
ICD-coded POP cases in UK, but only 13% of the Icelandic
POP cases. The effect sizes tended to be greater for the
association using cases that had undergone surgery compared
to those diagnosed only based on ICD code (Supplementary
Data 8). This most likely reflects increased severity of POP
among those that had undergone surgery or a greater number
of falsely diagnosed POP cases among the ICD based cases.
We conclude that our results based on ICD codes alone are
robust as the effects are in the same direction and the effect
sizes are not substantially different from those using surgically
treated POP cases.
We used LD score regression to estimate the SNP heritability of
POP33. Using LD scores for about 1.1 million variants found in
European populations we estimated SNP heritability in the meta-
analysis to be 12.4% (95% CI 9.9–14.8%).
Functional annotation and biological inference of risk loci.
None of the lead POP variants are coding or in high LD (r2 > 0.8)
with coding variants (Supplementary Data 3) and none was
highly correlated with the top cis-eQTL for neighboring genes in
any of the available tissues using mRNA expression data from the
GTEx database and our own RNA-sequence data on Icelandic
samples from blood (13,162 individuals) and adipose tissue (749
individuals).
To gain a further understanding of the variants associating
with POP we explored how they correlate with other traits in
combined data from Iceland and UKB – a database with
approximately 800 traits (P-value threshold= 0.05/800= 6.3 ×
10−5) – in addition to looking up all variants and their correlates
(r2 > 0.5) in the GWAS-catalog34 (Supplementary Data 9, 10). As
we observed overlaps of genetic association to different traits we
conducted adjusted association analyses (co-localization analyses)
at the POP loci to identify association results that are consistent
with a single signal representation (see Methods).
Six of the eight POP variants also associate with a total of 13
other phenotypes. Three of those variants associate with six
phenotypes with pathogenesis that may be the same as that of
POP. Two POP variants associate with conditions related to
estrogen exposure, rs3820282 at the WNT4 locus (leiomyoma of
uterus, gestational duration and endometriosis) and rs12325192
at the SALL1 locus (leiomyoma). The third, rs3791675 at the
EFEMP1 locus, associates with conditions related to aberrant
connective tissue function (hernias and carpal tunnel syndrome)
(Table 2).
Secondary, non-symptomatic diagnosis of POP through
conditions such as leiomyoma and endometriosis may introduce
a confounding of or biases in the association results from our
GWAS meta-analysis. We therefore tested the association of our
eight POP variants with POP after excluding endometriosis and
leiomyoma cases from the analysis. This did not affect effect or
significance substantially (Supplementary Data 11) indicating that
the POP associations are independent of endometriosis and
leiomyoma.
POP associated loci. The most significant POP association is
with rs3820282–T (P= 3.3 × 10−21, OR= 0.85), located in intron
1 of WNT4, which encodes a protein involved in development of
the female reproductive tract35. Loss of WNT4 function in
humans leads to underdevelopment and sometimes absence of
the uterus and vagina36. Variants correlated (r2 > 0.8) with the
POP-protecting allele rs3820282–T have been associated with
increased risk of endometriosis37, leiomyoma38, increased gesta-
tional duration39 and with decreased bone mineral density40
(Supplementary Data 10), all of which we replicate (Supple-
mentary Data 9). Rs3820282–T also associates with lower number
of children in our combined data (Supplementary Data 9). Our
co-localization analyses revealed that apart from the bone mineral
density and number of children signals, the association results for
leiomyoma, gestational duration, and endometriosis are likely to
be the same signal as the POP association at the locus (Supple-
mentary Data 12 and Table 2).
Rs12325192 is located near SALL1 and the POP-protecting
allele rs12325192–T is correlated (r2= 0.94) with rs66998222, a
variant we have previously reported to associate with leio-
myoma38; a trait that is positively correlated with estrogen
exposure (Table 2). Mutations in SALL1 have been associated
with Townes-Brocks syndrome, a condition associated with renal
malformation, suggesting a role of SALL1 in genitourinary
development41.
Two distinct POP variants, rs3791675 and rs1430191, are
located in and near EFEMP1 (also known as FBLN3), a gene
encoding fibulin-3. Fibulins are components of microfibrils, the
building blocks of elastic fibers that are generated in fibroblasts42
and provide tissue elasticity. EFEMP1 is expressed in mouse
connective tissue and network analyses suggest a role for EFEMP1
in connective tissue maintenance/homoeostasis43. Rare mutations
in EFEMP1 have been found to cause autosomal dominant Doyne
honeycomb degeneration of retina, characterized by yellow–white
deposits known as drusen that accumulate beneath the retinal
pigment epithelium44. The strongest POP association at the locus
is with rs3791675–T (P= 2.7 × 10−17, OR= 0.87). Its correlates
(r2 > 0.8) have been associated with various traits in Europeans,
including less height45,46, smaller BMI-adjusted waist
circumference47,48 and protection against inguinal hernia43
(Supplementary Data 10). We replicate these associations with
our data (Table 2). In addition, rs3791675–T associates with
protection against various hernias; inguinal hernia, femoral
hernia, umbilical, and ventral hernia, consistent with the
hypothesis of a similar proposed collagen pathophysiology for
POP and hernias49–52. Rs3791675–T also associates with
protection against diverticular disease, a disease in which
abnormal collagen and decreased tensile strength of the colonic
wall have been proposed to contribute to pathogenesis53. We
furthermore found rs3791675–T to associate with increased risk
of carpal tunnel syndrome – a condition also linked to connective
tissue metabolism54 – higher pulse pressure, and the lung
function ratio forced expiratory volume (FEV1)/forced vital
capacity (FVC) (Supplementary Data 9). According to our co-
localization analyses, association results for inguinal hernia,
height, FEV1/FVC, carpal tunnel syndrome, ventral hernia, and
waist circumference (Supplementary Data 12 and Table 2), are
consistent with a single signal origin.
Rs9306894, located in the 3′UTR of GDF7 (also known as
BMP12), associates with POP. GDF7 encodes a secreted ligand of
the TGF–beta superfamily of proteins and is thought to be
involved in tendon and ligament formation and repair55,56. The
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protein has been found to play a crucial role in tenogenesis of
mesenchymal stem cells and is used in tissue-engineering to treat
tendon injury57. A correlated variant near GDF7 (rs2289081–C,
r2= 0.85) has been associated with decreased pulse pressure58
and rs7255–T (r2= 0.62 to rs9306894) has been associated with
increased risk of Barrett’s oesophagus and esophageal adenocar-
cinoma combined (BE and EA) (Supplementary Data 10), which
we replicate (Supplementary Data 9) but co-localization analysis
only supports a single signal origin for BE and AE combined
(Supplementary Data 12). We replicate the previous association
of a highly correlated variant rs9306895 (r2= 0.996) with prostate
cancer59 (P= 6.15 × 10−6, OR= 1.07) (Table 2).
For the POP variant rs1247943, close to TBX5 (distance: 172
Kb), we replicate the previous associations of two highly
correlated variants with the POP risk-increasing allele;
rs1270884 (r2= 0.81) and rs2555019 (r2= 0.99) with increased
risk of prostate cancer60 and lowered risk of benign prostatic
hyperplasia61 (Table 2).
Rs7682992–T, the POP variant close to the FAT4 gene
(distance: 0.5 Mb), associates with increased risk of stress
incontinence (Table 2). FAT4 is part of the planar cell polarity
pathway that controls tissue organization; loss of FAT4 in mice
leads to cystic kidney disease62.
Rs72624976 is located in the 3′UTR of IMPDH1, one of two
target genes for the immunosuppressant drug mycophenolic acid63.
Mutations in IMPDH1 have been associated with the eye disorders
retinitis pigmentosa64 and Leber´s congenital amaurosis65.
Comorbidity. To test further for comorbidity between POP and
other traits, we collected sequence variants reported to associate
with traits that associate with one or more of our POP variants:
leiomyoma (N= 32)38,66, gestational duration (N= 5)39, endo-
metriosis (N= 27)67, BE and AE combined (N= 14)68, prostate
cancer (N= 145)59, inguinal hernia (N= 4)43, height
(N= 3,290)69, FEV1/FVC (N= 52)70, BMI-adjusted waist
circumference (N= 70)48 and benign prostatic hyperplasia
(N= 23)61. Of the 3,652 unique variants collected, 17 were cor-
related within height (r2 > 0.8). We tested these 3,635 (3652–17)
independent sequence variants for association with POP. As 44
variants were correlated across traits (r2 > 0.8), we used the sig-
nificance threshold of P < 1.4 × 10−5 (0.05/3591) (3652-17-44=
3591) (Supplementary Data 13–22). We found variants at nine
loci to associate with POP; five of which associate at genome-wide
significance with POP, three that were previously associated with
height (P < 1.4 × 10−5) at TXNDC5 (6p24.3), SLC12A2 (5q23.3)
and LOXL1 (15q24.1) (Supplementary Data 19) and one at WT1
that associates with inguinal hernia (11p13) (Supplementary
Data 18).
We further used the variants collected for each of the ten traits
as instruments to explore a possible causal relationship between
each trait and POP71. By regressing the effect estimates of each
group of variants (trait-specific) on POP on the effect estimates of
those variants on the corresponding traits, using AF × (1-AF) as a
weight72, we did not observe a correlation between the effect
estimates (Supplementary Fig. 3).
We also plotted the POP effects of the eight POP variants
against their effects on the 13 traits listed in Table 2 (Iceland and
UKB combined, apart from height and gestational duration which
are data from Iceland) (Supplementary Fig. 4). It is apparent that
although a handful of variants associate with POP and other
phenotypes, there is little overlap between the variants associating
with POP and the other phenotypes and little correlation between
effect estimates. We are not aware of previous literature findings
showing associations of these phenotypes within POP cases and
their family members.
BMI is not associated with POP at the genetic level. We
screened for evidence of a genetic relationship of POP and two of
the most consistently reported risk factors for POP in addition to
age; BMI and number of children. We verified that variants
reported to associate with BMI73,74 or number of children75 do
not associate with POP (Supplementary Data 23, 24) and that
adding BMI or number of children separately as covariates in our
models did not affect the effect sizes or significance of the eight
lead variants when tested for association with POP (Supple-
mentary Data 25). Furthermore, no correlation was found
between effect estimates of BMI- or number of children sequence
variants and their effects on POP and vice versa (Supplementary
Figs. 5, 6). Using polygenic risk scores for POP, we saw little
evidence of association with number of children (P-value= 9.5 ×
10−5, beta= 0.015) in Iceland only and none with BMI (Sup-
plementary Data 26). For BMI, we found no evidence of causal
relationship with POP at the genetic level. With that in mind, and
since only one of the POP variants (rs3820282) associates with
number of children we do not find strong support for a causal
pathway or a common third factor affecting POP and those two
traits.
Discussion
We conducted a meta-analysis of two GWAS for POP and dis-
covered eight variants at seven loci that associate with POP. Two
sequence variants, rs3820282 at WNT4 and rs12325192 near
SALL1 also associate with other traits that are strongly affected by
estrogen exposure, i.e. leiomyoma (rs3820282 and rs12325192),
gestational duration (rs3820282) and endometriosis (rs3820282).
Of the 23 correlated variants at the 1p36.12 locus, rs3820282 has
the best functional candidacy. Rs3820282–T resides in a region
marked by mono-methylation of histone H3 at lysine residue K4
(H3K4me1), a characteristic of enhancers, and is predicted to
alter a conserved binding site for the transcription factors (TFs)
ESR1 and ESR276 supported by ChIP-seq data in breast and bone
cell lines77. This suggests that the variant may alter the estrogen-
based regulation of WNT4 or adjacent genes39. A previous report
showed chromatin looping between the region containing
rs12038474 (LD to rs3820282; r2= 0.81) and CDC42 in endo-
metrial adenocarcinoma78. Our analysis of available Hi-C data79
along with enhancer-gene predictions80 suggests WNT4, HSPG2,
and CDC42 as possible enhancer-gene targets, using relevant cell-
types and tissues. Based on the role of WNT4 in female sex organ
development35,WNT4 can be considered to be a strong candidate
gene at the locus. One of the eight POP variants, rs3791675 at
EFEMP1, associates with traits with proposed collagen patho-
physiology, i.e. inguinal hernia, ventral hernia and carpal tunnel
syndrome. Furthermore, two genes at POP associated loci, GDF7
and EFEMP1, have functions related to connective tissue
metabolism.
We find that the overlap between POP variants and other traits
are limited to distinct signals and thus do not allow for strong
inference regarding common pathways or causal relationships.
However, the pleiotropy found at three of the POP loci, where the
associating traits have similar proposed pathophysiology as POP,
together with the known functions of the proposed target genes,
may fuel further explorations of the possible role of estrogen
exposure and connective tissue metabolism in the etiology of
POP. Through analysis of variants that are reported to associate
with conditions that associate with one or more of our POP
variants, we identified four additional POP variants, three that
associate with height and one with inguinal hernia.
In mice, a POP phenotype has been associated with knock-
down of fibulin 3 (EFEMP1), lysyl oxidase like 1 (LOXL1), fibulin
5 (FBLN5), and homeobox A11 (HOXA11) as summarized in a
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recent review on key genes and pathways for POP81. Of those
four genes, variants at the EFEMP1 locus associate with POP in
our data and, through analysis of height variants, also a variant at
the LOXL1 locus; rs12440667–T (P= 3.6 × 10−6, OR= 0.94)
(Supplementary Data 19, Supplementary Fig. 7). EFEMP1
encodes fibulin–3 but members of the fibulin family of extra-
cellular matrix (ECM) proteins have been found to be important
in elastic fiber assembly82,83. The two EFEMP1 mouse knockout
studies reported to date84,85 demonstrate an abnormality in the
integrity of elastic fibers in fascia connective tissue and connective
tissue of the vaginal wall with abnormal pelvic organ support in
addition to increased activity of matrix metalloprotease (MMPs)
that degrade matrix collagen in connective tissue. These mice also
displayed an early onset of aging-associated traits including
decreased body mass, lordokyphosis, reduced hair growth, and
generalized fat, muscle and organ atrophy, as well as reduced
lifespan. The POP variants in and near to EFEMP1 did not
associate with traits likely to cause lordokyphosis (any fracture
and osteoporosis in the ICE-UKB data, and BMD (hip and spine
measures)), BMI (both sexes and females only) or lifespan
(females) in the Icelandic data (Supplementary Data 27).
In this paper, we report the first set of genome-wide significant
POP variants identified through GWAS. The genetic overlap
observed between POP and several traits with similar patho-
physiology point towards a role of estrogen exposure and con-
nective tissue metabolism in the etiology of POP. The results
provide new insights for future research to further the under-
standing of POP.
Methods
Datasets. The meta-analysis combined the results of two GWA studies of pelvic
organ prolapse (POP). The Icelandic data originates from Landspitali – The
National University Hospital Inpatient Registry from January 1983 to August 2018.
A total of 3,699 women had a POP diagnosis (ICD10 code N81 or ICD9 code 618).
Controls were recruited through different genetic research projects at deCODE
genetics. We had genotype information for 92% of the POP cases, so that the
Icelandic dataset consisted of 3409 cases and 131,444 female controls. The UK
Biobank data (UKB) consists of 11,601 cases and 209,228 controls of European
ancestry (self-reported white British with similar genetic ancestry based on prin-
cipal component analysis and with consistent reported and genetically determined
gender)86, recruited between 2006 and 2010 aged 40–69, and with follow-up until
201687. The UKB cases had ICD10 code N81 in hospital inpatient records, with
data dating back to between 1981 and 1997, depending on the external source
(Hospital Episode Statistics from England (89% of participants), Patient Episode
Database for Wales (7%) and Scottish Morbidity Record (7%)) and include primary
and secondary diagnosis of POP (http://biobank.ctsu.ox.ac.uk/showcase/docs/
inpatient_mapping.pdf).
Hospital-based POP diagnosis are likely to be stage II or greater, according to
the POPQ standardized grading system5. Furthermore, the ratio of cases to controls
in the datasets (0.055 in UKB and 0.026 in ICE) are consistent with reported
prevalence estimates that use POPQ stage II–IV as a criterion for diagnosis or with
symptom-based prevalence estimates8–11. The 2-fold difference in the ratio of cases
to controls of POP in UKB data compared to the data from Iceland is explained by
the difference in age-distributions (Supplementary Data 1). To further compare the
POP phenotype between Iceland and UKB, we compared the percentage of cases
within each of the nine subgroups of ICD10 code N81. In both datasets the
majority of cases are diagnosed with cystocele or rectocele and fewer with
uterovaginal prolapse (Supplementary Data 28).
The leiomyoma38, benign prostatic hyperplasia61, prostate cancer61,
endometriosis37, diverticular disease88, and lung function70 datasets have been
described previously. We obtained blood pressure measurements from Landspitali
– The National University Hospital of Iceland, the Primary Health Care Clinics of
the Reykjavik area and at recruitment for deCODE studies. Data on gestational
duration (GD) (Iceland only) for the first available pregnancy was obtained from
the National Birth Registry, excluding multiple pregnancies, stillbirths and pre and
post term births (GD ≤259 days and GD ≥301 days) and adjusting for age of
mother, sex, and year of birth of the child. Information on number of children was
extracted from deCODE geneology database, adjusting for year of birth and county.
Information on BMI was corrected for year of birth, age and county, conditional on
age >18. BMI values originate from measured and self-reported data and are mean
values for multiple measures within individuals. Waist circumference measurement
was adjusted for age, gender, and BMI, conditional on age > 18. The BMD values at
head (DEXA, Hologic QDR4500A) were age, height and body mass index corrected
(Iceland only). Quantitative traits were rank-based inverse normal transformed to a
standard normal distribution separately for each gender. Other datasets from
Iceland originate from deCODE genetics phenotype database which contains
extensive medical information on various diseases and other traits. Cases with
hernias were identified by hospital-based ICD10 diagnosis codes: K40 (inguinal
hernia), K41 (femoral hernia), K43 (ventral hernia) in both datasets; Iceland and
UKB and the same applies for diverticular disease (K57), stress incontinence
(N393), carpal tunnel syndrome (G560), Barrett’s oesophagus and esophageal
adenocarcinoma combined (K227 and C15, data in UKB only), and actinic
keratosis (L57). For sex specific phenotypes in Iceland, only controls for the
relevant sex were included in the analysis.
The study was approved by the Icelandic National Bioethics Committee
(bioethics consent number VSN 18-067) in agreement with conditions issued by
the Data Protection Authority of Iceland. Written informed consent was obtained
from all genotyped subjects. Personal identities relating to participants’ data and
biological samples (i.e. blood samples, buccal samples, or adipose tissue samples)
were encrypted by a third-party system (Identity Protection System), approved and
monitored by the Data Protection Authority89. DNA was extracted from blood and
buccal samples and RNA from blood and adipose tissue samples.
Genotyping and imputation. Details of genotyping and imputation methods in
the Icelandic part of the study have been described90. In brief, the whole genomes
of 15,220 Icelanders, participating in various disease projects at deCODE genetics,
were sequenced to a mean depth of at least 10× (median 32×) using Illumina
technology. Genotypes of SNPs and indels were called using joint calling with the
Genome Analysis Toolkit HaplotypeCaller (GATK version 3.4.07)91. As all of the
sequenced individuals had also been chip-typed and long-range phased, informa-
tion about haplotype sharing was used to improve genotype calls. In total, 151,677
Icelanders have been genotyped with various Illumina SNP chips, long-range
phased and imputed based on the sequenced data set92. Using genealogic infor-
mation, genotype probabilities for 282,894 untyped relatives of the genotyped
individuals were calculated to further increase the sample size for association
analysis and to increase the power to detect associations.
The informativeness of genotype imputation was estimated by the ratio of the
variance of imputed expected allele counts and the variance of the actual allele
counts:
Var E θjchip datað Þð Þ
Var θð Þ
where θ is the allele count. Here, Var E θjchip datað Þð Þ is estimated by the observed
variance in the imputed expected counts and Var(θ) was estimated by p (1− p),
where p is the allele frequency. Variants were annotated using Ensembl release 80
and Variant Effect Predictor (VEP) version 2.893.
Genotyping of UKB samples was performed using a custom-made Affymetrix
chip, UK BiLEVE Axiom94 in the first 50,000 participants and with the Affymetrix
UK Biobank Axiom array95 in the remaining participants with 95% of the signals
on both chips. Imputation was performed by Wellcome Trust Centre for Human
Genetics using a combination of the Haplotype Reference Consortium (HRC),
1000 Genomes phase 3 and the UK10K haplotype resources86. This yields a total of
92.6 million imputed variants, however, we used only markers that were imputed
on the basis of the HRC panel owing to problems in the UK10K+ 1000 Genomes
panel imputation, resulting in 37.1 million imputed variants used in the
current study.
GWAS and meta-analysis. We used logistic regression assuming an additive
model in the case-control analysis to test for association between variants and
disease, treating disease status as the response and expected genotype counts from
imputation as covariates, and using likelihood ratio test to compute P-values. For
the Icelandic data, the model also includes as nuisance variables available indivi-
dual characteristics that correlate with phenotype status. In Iceland, these covari-
ates are: county of birth, current age or age at death (first and second order terms
included), availability of blood sample for the individual and an indicator function
for the overlap of the lifetime of the individual with the time span of phenotype
collection. The association analysis for both the Icelandic and UKB datasets was
done using software developed at deCODE genetics90. For the association testing in
UKB, 40 principal components were used to adjust for population substructure and
age was included as a covariate in the logistic regression model.
To account for inflation in test statistics due to cryptic relatedness and
stratification, we applied the method of linkage disequilibrium (LD) score
regression33. LD scores were downloaded from an LD score database (ftp://atguftp.
mgh.harvard.edu/brendan/1k_eur_r2_hm3snps_se_weights.RDS; accessed 23 June
2015). With a set of 1.1 million variants, we regressed the χ2 statistics from our
GWAS scan on the LD scores and used the intercept as a correction factor. P values
were then adjusted by dividing the corresponding χ2 values by the correction
factors. The estimated correction factor for POP based on LD score regression was
1.12 for the Icelandic and 1.05 for the UK datasets, respectively.
Variants in the UKB imputation dataset were mapped to National Center for
Biotechnology Information (NCBI) Genome Reference Consortium Build 38
positions (GRCh38) and matched to the variants in the Icelandic dataset based on
allele variation. Only sequence variants from the Haplotype Reference Consortium
panel (HRC) were included in the meta-analysis. The results from the two datasets
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were combined using a fixed effect model (a Mantel-Haenszel model)96 in which
the datasets were allowed to have different population frequencies for alleles and
genotypes but were assumed to have a common OR and weighted with the inverse
of the variance. We selected a threshold of 0.8 imputation info and MAF >0.01%
for variants available in the Icelandic data set and/or the UKB data set. A total of
37,144,863 variants were used in the analysis. We tested for heterogeneity by
comparing the null hypothesis of the effect being the same in both populations to
the alternative hypothesis of each population having a different effect using a
likelihood ratio test (Cochran´s Q) reported as Phet (Table 1 for POP and
Supplementary Data 29 for other traits).
We used the weighted Bonferroni method to account for all 37,144,863 variants
being tested (P-value < (0.05 × weight)/37,144,863). Using the weights given in
Sveinbjornsson et al.32, this procedure controls the family-wise error rate at 0.05;
P ≤ 2.2 × 10−7 for high-impact variants (including stop-gained, frameshift, splice
acceptor or donor and initiator codon variants, N= 9,658), P ≤ 4.4 × 10−8 for
missense, splice-region variants and in-frame-indels (N= 180,803), P ≤ 4.0 × 10−9
for low-impact variants (including synonymous, 3′ and 5′ UTR, and upstream and
downstream variants, N= 2,653,622), P ≤ 6.7 × 10−10 for intron and intergenic
variants (N= 34,300,780) (Supplementary Data 2). All P-values are two-sided.
Conditional analysis. We applied approximate conditional analyses, implemented
in the GCTA software97 to the meta-analysis summary statistics to look for
additional association signals at each of the genome-wide significant loci. LD
between variants was estimated using a set of 8700 whole-genome sequenced
Icelandic individuals. The analysis was restricted to variants present in both the
Icelandic and UKB datasets and within 1 Mb from the index variants. We tested 7
loci and about 100,000 variants in the conditional analysis and report one variant
(rs1430191) with conditional P value < 5 × 10−7. The results from GCTA were
verified by conditional analysis using genotype data in the Icelandic and UK
datasets separately and results presented in Table 1 are obtained by meta-analyzing
those results.
Co-localization analysis. The variants explored as potentially representing the
same signal as the POP variants were found by two means. First, we looked up
correlates of the POP variants in the GWAS-catalog (r2 > 0.5) (Supplementary
Data 10) and extracted those with 0.5 < r2 < 0.9 for the co-localization analysis
because of the limited potential to distinguish between variants in LD of r2 > 0.9.
Second, for each of the traits associating with the POP variants in our data we
extracted the strongest associating variant (r2 < 0.9) for the adjusted (conditional)
analysis. For the tests performed in the co-localization analysis, we use previously
reported variants as index variants for the secondary traits when available for a
conditional analysis, given that the reported analyses are based on a similar sized or
a larger sample than our combined data from Iceland and UKB. Otherwise we use
the variant most strongly associating with the trait in our data. The results from the
conditional analyses are consistent with a single signal representation if two con-
ditions are met: First, the P-value of the index variant for the secondary trait is
≥0.05 after adjusting for the POP variant at the locus and second, the POP variant
at the locus associates with the secondary trait at a P-value < 6.3 × 10−5. The latter
condition holds for traits identified through the phenomescan (PheWAS) but a P-
value < 0.05 is required if a correlate of the POP variant is previously reported to
associate with the trait in a considerably larger sample than in our data (Supple-
mentary Data 12).
RNA sequencing analysis. Generation of poly(A)+ complementary DNA
sequencing libraries, RNA sequencing, and data processing were carried out as
described previously98,99. Two tissue types were available for this analysis: whole
blood (N= 13,162) and adipose tissue (N= 749). We used generalized linear
regression to test for association between sequence variants and rank-transformed
gene expression estimates.
Polygenic scores, heritability, and functional annotation. We calculated two sets
of polygenic risk scores (PRSsPOP) both using Icelandic and UK data essentially as
previously described100. Briefly, the PRSs were calculated using genotypes for about
630,000 autosomal markers included on the Illumina SNP chips to avoid uncer-
tainty due to imputation quality. We estimated linkage disequilibrium (LD)
between markers using 14,938 phased Icelandic samples and used this LD infor-
mation to calculate adjusted effect estimates using LDpred100,101. To avoid over-
fitting do to population substructure, the effect estimates calculated using the
Icelandic data were used as weights when generating the weighted PRS (PRSPOPICE)
for testing in the UK, and the effect estimates generated from the UK data were
used to derive the weighted PRS (PRSPOPUKB) for testing in Iceland. We created
several PRSs assuming different fractions of causal variants (the P parameter in
Ldpred), and selected the best PRS based on prediction of POP in the Icelandic and
UK datasets (1% causal variants). The most predictive PRSPOPICE was then used to
calculate the correlation with selected phenotypes in the UKB data, and the most
predictive PRSPOPUKB was tested for correlation with the selected phenotypes in
Iceland. The correlation between the PRS and phenotypes was calculated using
logistic regression in R (v3.5) (http://www.R-project.org) adjusting for year of birth
and principle components by including them as covariates in the analysis. We
summarize the correlation of the two sets of PRS scores calculated with the Ice-
landic and UKB phenotypes as weighted average of the effect estimates from both
analyses.
Using precomputed LD scores for about 1.1 million variants found in European
populations (downloaded from: https://data.broadinstitute.org/alkesgroup/
LDSCORE/eur_w_ld_chr.tar.bz2), we estimated SNP heritability with LD score
regression33.
Chromatin interaction map data were derived from Hi-C sequencing for
selected cell- and tissue types79. The data were downloaded from Omnibus,
accession number GSE87112, in pre-processed format (Fit-Hi-C algorithm)
representing false-discovery rates (FDR) for contact regions at 40 kb resolution.
To define statistically significant contacts we used a threshold value of FDR <10
−6 in relevant cell-types and tissue (IMR90 fibroblasts, mesenchymal stem cells,
and muscle tissue i.e. left ventricle, right ventricle, and psoas muscle)79. DNA
contact regions containing the lead variant, or those containing variants in LD
(r2 > 0.8) to the lead variant, were then identified to find interacting target genes.
Using JEME (joint effect of multiple enhancers)80, we similarly looked for
enhancer elements containing the lead variant (and those in LD) to find target
genes using similar cell- and tissue types (IMR90 fibroblasts, mesenchymal stem
cells, and muscle tissue i.e. colon, stomach, duodenum, and male skeletal
muscle). The intersection of genes identified by Hi-C and JEME are then
regarded as strong candidate gene targets.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The Icelandic population WGS data has been deposited at the European Variant Archive
under accession code PRJEB15197. We declare that the data supporting the findings of
this study are available within the article, its Supplementary Data files and upon
reasonable request. A reporting summary for this Article is available as a Supplementary
Information file. The UK Biobank data can be obtained upon application (ukbiobank.ac.
uk). The genome-wide association scan summary data will be made available at http://
www.decode.com/summarydata.
Code availability
We use the following publicly available software in conjunction with the above-described
algorithms in the sequencing processing pipeline (whole-genome sequencing, association
testing, RNA-sequencing mapping and analysis): BWA 0.7.10 mem, https://github.com/
lh3/bwa; GenomeAnalysisTKLite 2.3.9, https://github.com/broadgsa/gatk/; Picard tools
1.117, https://broadinstitute.github.io/picard/; SAMtools 1.3, http://samtools.github.io/;
Bedtools v2.25.0-76-g5e7c696z, https://github.com/arq5x/bedtools2/; Variant Effect
Predictor, https://github.com/Ensembl/ensembl-vep; BOLT-LMM, https://data.
broadinstitute.org/alkesgroup/BOLT-LMM/downloads/; LDSC (LD Score), https://
github.com/bulik/ldsc.
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